Adicet Bio (ACET) Expected to Announce Quarterly Earnings on Tuesday

Adicet Bio (NASDAQ:ACET) is anticipated to post its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect the company to announce earnings of ($3.13) per share for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:00 PM ET.

Adicet Bio (NASDAQ:ACET) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($2.94) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.23) by $0.29. On average, analysts expect Adicet Bio to post $-10 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Adicet Bio Stock Down 0.8%

Shares of ACET stock traded down $0.07 during trading on Tuesday, reaching $7.87. The company’s stock had a trading volume of 4,189 shares, compared to its average volume of 157,839. Adicet Bio has a one year low of $6.01 and a one year high of $17.44. The business has a fifty day moving average price of $7.21 and a 200-day moving average price of $8.78. The company has a market cap of $75.50 million, a price-to-earnings ratio of -0.44 and a beta of 1.57.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on ACET shares. HC Wainwright lowered their price target on shares of Adicet Bio from $50.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, March 23rd. Truist Financial raised Adicet Bio to a “strong-buy” rating in a research report on Wednesday, March 25th. Canaccord Genuity Group set a $18.00 target price on Adicet Bio and gave the stock a “buy” rating in a report on Tuesday, January 6th. Weiss Ratings upgraded Adicet Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. Finally, Guggenheim cut their price objective on Adicet Bio from $128.00 to $100.00 and set a “buy” rating for the company in a report on Friday, March 13th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Adicet Bio currently has a consensus rating of “Moderate Buy” and an average price target of $56.25.

Insider Activity

In other news, major shareholder Ra Capital Management, L.P. bought 74,751 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The stock was acquired at an average cost of $7.27 per share, for a total transaction of $543,439.77. Following the purchase, the insider owned 1,182,624 shares of the company’s stock, valued at approximately $8,597,676.48. This trade represents a 6.75% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Over the last quarter, insiders have bought 223,596 shares of company stock valued at $1,603,934. 4.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Adicet Bio

Institutional investors and hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. lifted its position in shares of Adicet Bio by 1.7% in the first quarter. Goldman Sachs Group Inc. now owns 3,816,556 shares of the company’s stock valued at $2,882,000 after buying an additional 63,691 shares during the last quarter. Two Sigma Investments LP increased its holdings in shares of Adicet Bio by 66.6% during the 3rd quarter. Two Sigma Investments LP now owns 854,568 shares of the company’s stock worth $692,000 after acquiring an additional 341,761 shares during the last quarter. Franklin Resources Inc. bought a new stake in Adicet Bio in the 4th quarter valued at $5,276,000. Citadel Advisors LLC lifted its holdings in Adicet Bio by 19.8% during the 3rd quarter. Citadel Advisors LLC now owns 583,948 shares of the company’s stock valued at $473,000 after purchasing an additional 96,342 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in Adicet Bio during the 4th quarter valued at $2,310,000. Institutional investors own 83.89% of the company’s stock.

Adicet Bio Company Profile

Adicet Bio, Inc (NASDAQ: ACET) is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company’s proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.

Adicet’s lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies.